| Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer KC Patra, Q Wang, PT Bhaskar, L Miller, Z Wang, W Wheaton, N Chandel, ... Cancer cell 24 (2), 213-228, 2013 | 820 | 2013 |
| FoxM1, a critical regulator of oxidative stress during oncogenesis HJ Park, JR Carr, Z Wang, V Nogueira, N Hay, AL Tyner, LF Lau, ... The EMBO journal 28 (19), 2908-2918, 2009 | 262 | 2009 |
| FoxM1 mediates resistance to herceptin and paclitaxel JR Carr, HJ Park, Z Wang, MM Kiefer, P Raychaudhuri Cancer research 70 (12), 5054-5063, 2010 | 210 | 2010 |
| Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models Z Wang, K Sun, Y Xiao, B Feng, K Mikule, XY Ma, N Feng, CP Vellano, ... Scientific reports 9 (1), 1853, 2019 | 200 | 2019 |
| Deregulation of FoxM1b leads to tumour metastasis HJ Park, G Gusarova, Z Wang, JR Carr, J Li, KH Kim, J Qiu, YD Park, ... EMBO molecular medicine 3 (1), 21-34, 2011 | 167 | 2011 |
| A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models K Sun, K Mikule, Z Wang, G Poon, A Vaidyanathan, G Smith, ZY Zhang, ... Oncotarget 9 (98), 37080, 2018 | 130 | 2018 |
| A conserved phosphorylation site within the forkhead domain of FoxM1B is required for its activation by cyclin-CDK1 YJ Chen, C Dominguez-Brauer, Z Wang, JM Asara, RH Costa, AL Tyner, ... Journal of biological chemistry 284 (44), 30695-30707, 2009 | 104 | 2009 |
| Essential roles of FoxM1 in Ras-induced liver cancer progression and in cancer cells with stem cell features D Kopanja, A Pandey, M Kiefer, Z Wang, N Chandan, JR Carr, R Franks, ... Journal of hepatology 63 (2), 429-436, 2015 | 93 | 2015 |
| An N-terminal inhibitory domain modulates activity of FoxM1 during cell cycle HJ Park, Z Wang, RH Costa, A Tyner, LF Lau, P Raychaudhuri Oncogene 27 (12), 1696-1704, 2008 | 91 | 2008 |
| FoxM1 in Tumorigenicity of the Neuroblastoma Cells and Renewal of the Neural Progenitors Z Wang, HJ Park, JR Carr, Y Chen, Y Zheng, J Li, AL Tyner, RH Costa, ... Cancer research 71 (12), 4292-4302, 2011 | 90 | 2011 |
| Protein tyrosine kinase 6 directly phosphorylates AKT and promotes AKT activation in response to epidermal growth factor Y Zheng, M Peng, Z Wang, JM Asara, AL Tyner Molecular and cellular biology 30 (17), 4280-4292, 2010 | 81 | 2010 |
| FoxM1 regulates mammary luminal cell fate JR Carr, MM Kiefer, HJ Park, J Li, Z Wang, J Fontanarosa, D DeWaal, ... Cell reports 1 (6), 715-729, 2012 | 80 | 2012 |
| Exploitation of diagnostic computed tomography scans to assess the impact of nutrition support on body composition changes in respiratory failure patients CA Braunschweig, PM Sheean, SJ Peterson, S Gomez Perez, S Freels, ... Journal of Parenteral and Enteral Nutrition 38 (7), 880-885, 2014 | 74 | 2014 |
| Protein tyrosine kinase 6 protects cells from anoikis by directly phosphorylating focal adhesion kinase and activating AKT Y Zheng, J Gierut, Z Wang, J Miao, JM Asara, AL Tyner Oncogene 32 (36), 4304-4312, 2013 | 66 | 2013 |
| PTK6 activation at the membrane regulates epithelial–mesenchymal transition in prostate cancer Y Zheng, Z Wang, W Bie, PM Brauer, BE Perez White, J Li, V Nogueira, ... Cancer research 73 (17), 5426-5437, 2013 | 56 | 2013 |
| PTK6/BRK is expressed in the normal mammary gland and activated at the plasma membrane in breast tumors M Peng, R Emmadi, Z Wang, EL Wiley, PH Gann, SA Khan, N Banerji, ... Oncotarget 5 (15), 6038, 2014 | 40 | 2014 |
| Pharmacological inhibition of PARP6 triggers multipolar spindle formation and elicits therapeutic effects in breast cancer Z Wang, SE Grosskurth, T Cheung, P Petteruti, J Zhang, X Wang, W Wang, ... Cancer research 78 (23), 6691-6702, 2018 | 36 | 2018 |
| Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models S Kumar, S Ghosh, G Sharma, Z Wang, MR Kehry, MH Marino, TY Neben, ... MAbs 13 (1), 1954136, 2021 | 28 | 2021 |
| An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): Cohort A of … J Liu, S Gaillard, AW Hendrickson, J Moroney, O Yeku, E Diver, ... Gynecologic Oncology 162, S17-S18, 2021 | 26 | 2021 |
| Targeting FoxM1 effectively retards p53-null lymphoma and sarcoma Z Wang, Y Zheng, HJ Park, J Li, JR Carr, Y Chen, MM Kiefer, D Kopanja, ... Molecular cancer therapeutics 12 (5), 759-767, 2013 | 23 | 2013 |
